Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · IEX Real-Time Price · USD
3.551
+0.041 (1.17%)
Apr 26, 2024, 12:47 PM EDT - Market open
Company Description
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension.
It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.
Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Tenax Therapeutics, Inc.
| Country | United States |
| Founded | 1967 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Christopher T. Giordano |
Contact Details
Address: 101 Glen Lennox Drive, Suite 300 Chapel Hill, North Carolina 27517 United States | |
| Phone | 919-855-2100 |
| Website | tenaxthera.com |
Stock Details
| Ticker Symbol | TENX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000034956 |
| CUSIP Number | 88032L209 |
| ISIN Number | US88032L6056 |
| Employer ID | 26-2593535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher T. Giordano | Chief Executive Officer, President and Director |
| Dr. Stuart Rich M.D. | Chief Medical Officer and Director |
| Lawrence R. Hoffman CPA, Esq. | Interim Chief Financial Officer |
| Doug Randall | Executive Vice President of Commercial and Business Operations |
| Dr. Douglas Hay | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 12, 2024 | EFFECT | Notice of Effectiveness |
| Apr 12, 2024 | EFFECT | Notice of Effectiveness |
| Apr 11, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 11, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 424B3 | Prospectus |